Scoop: With investor interest dried up in microbiome therapies, DermBiont pivots to other topicals and nears close of Series B

Kyle LaHucik

Senior Reporter

DermBiont axed trials of its original lead dermatology gel, the biotech confirmed to Endpoints News, and with little investor appetite for microbiome-based therapies, the company …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Scoop: With investor interest dried up in microbiome therapies, DermBiont pivots to other topicals and nears close of Series B

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Patient dies in Neurogene's Rett syndrome study

Sanofi introduces new 340B payment model — report

Are programs with compounded GLP-1s safe for your population?

Scoop: With in­vestor in­ter­est dried up in mi­cro­bio­me ther­a­pies, DermBiont piv­ots to oth­er top­i­cals and nears close of Se­ries B

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Sanofi in­tro­duces new 340B pay­ment mod­el — re­port

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Scoop: With investor interest dried up in microbiome therapies, DermBiont pivots to other topicals and nears close of Series B

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Patient dies in Neurogene's Rett syndrome study

Sanofi introduces new 340B payment model — report

Are programs with compounded GLP-1s safe for your population?